11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)

. 2024 Jun 15 ; 24 (1) : 736. [epub] 20240615

Jazyk angličtina Země Velká Británie, Anglie Médium electronic

Typ dokumentu klinické zkoušky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid38879476
E-zdroje Online Plný text
Odkazy

PubMed 38879476
PubMed Central PMC11179343
DOI 10.1186/s12885-024-12469-2
PII: 10.1186/s12885-024-12469-2
Knihovny.cz E-zdroje

BACKGROUND: Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If postoperative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is used for radiotherapy treatment planning. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery and is called rapid early progression (REP). Radiotherapy planning is currently based on MRI for target volumes definitions in many radiotherapy facilities. However, patients with REP may benefit from targeting radiotherapy with other imaging modalities. The purpose of the presented clinical trial is to evaluate the utility of 11C-methionine in optimizing radiotherapy for glioblastoma patients with REP. METHODS: This study is a nonrandomized, open-label, parallel-setting, prospective, monocentric clinical trial. The main aim of this study was to refine the diagnosis in patients with GBM with REP and to optimize subsequent radiotherapy planning. Glioblastoma patients who develop REP within approximately 6 weeks after surgery will undergo 11C-methionine positron emission tomography (PET/CT) examinations. Target volumes for radiotherapy are defined using both standard planning T1-weighted contrast-enhanced MRI and PET/CT. The primary outcome is progression-free survival defined using RANO criteria and compared to a historical cohort with REP treated without PET/CT optimization of radiotherapy. DISCUSSION: PET is one of the most modern methods of molecular imaging. 11C-Methionine is an example of a radiolabelled (carbon 11) amino acid commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. Optimized radiotherapy may also have the potential to cover those regions with a high risk of subsequent progression, which would not be identified using standard-of-care MRI for radiotherapy planning. This is one of the first study focused on radiotherapy optimization for subgroup of patinets with REP. TRIAL REGISTRATION: NCT05608395, registered on 8.11.2022 in clinicaltrials.gov; EudraCT Number: 2020-000640-64, registered on 26.5.2020 in clinicaltrialsregister.eu. Protocol ID: MOU-2020-01, version 3.2, date 18.09.2020.

Zobrazit více v PubMed

Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020;22(8):1073–1113. doi: 10.1093/neuonc/noaa106. PubMed DOI PMC

Weller M, van den Bent M, Preusser M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood [published correction appears in Nat Rev Clin Oncol. 2022 May;19(5):357-358] Nat Rev Clin Oncol. 2021;18(3):170–186. doi: 10.1038/s41571-020-00447-z. PubMed DOI PMC

Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi: 10.1056/NEJMoa043330. PubMed DOI

Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. doi: 10.1016/S1470-2045(09)70025-7. PubMed DOI

Lakomy R, Kazda T, Selingerova I, et al. Real-world evidence in glioblastoma: stupp's regimen after a decade. Front Oncol. 2020;10:840. doi: 10.3389/fonc.2020.00840. PubMed DOI PMC

Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306–2316. doi: 10.1001/jama.2017.18718. PubMed DOI PMC

Kazda T, Dziacky A, Burkon P, et al. Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp's Trial: more controversies than standards? Radiol Oncol. 2018;52(2):121–128. doi: 10.2478/raon-2018-0023. PubMed DOI PMC

Perry JR, Laperriere N, O'Callaghan CJ, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–1037. doi: 10.1056/NEJMoa1611977. PubMed DOI

Farace P, Amelio D, Ricciardi GK, et al. Early MRI changes in glioblastoma in the period between surgery and adjuvant therapy. J Neurooncol. 2013;111(2):177–185. doi: 10.1007/s11060-012-0997-y. PubMed DOI

Palmer JD, Bhamidipati D, Shukla G, et al. Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients. Am J Clin Oncol. 2019;42(5):481–486. doi: 10.1097/COC.0000000000000537. PubMed DOI

Lakomy R, Kazda T, Selingerova I, et al. Pre-radiotherapy progression after surgery of newly diagnosed glioblastoma: corroboration of new prognostic variable. Diagnostics (Basel). 2020;10(9):676. doi: 10.3390/diagnostics10090676. PubMed DOI PMC

Wee CW, Kim E, Kim TM, et al. Impact of interim progression during the surgery-to-radiotherapy interval and its predictors in glioblastoma treated with temozolomide-based radiochemotherapy. J Neurooncol. 2017;134(1):169–175. doi: 10.1007/s11060-017-2505-x. PubMed DOI

Merkel A, Soeldner D, Wendl C, et al. Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials. J Neurooncol. 2017;132(2):249–254. doi: 10.1007/s11060-016-2362-z. PubMed DOI PMC

Villanueva-Meyer JE, Han SJ, Cha S, Butowski NA. Early tumor growth between initial resection and radiotherapy of glioblastoma: incidence and impact on clinical outcomes. J Neurooncol. 2017;134(1):213–219. doi: 10.1007/s11060-017-2511-z. PubMed DOI PMC

Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl J Med. 2005;352:997–1003. doi: 10.1056/NEJMoa043331. PubMed DOI

Sana J, Hajduch M, Michalek J, et al. MicroRNAs and glioblastoma: Roles in core signalling pathways and potential clinical implications. J Cell Mol Med. 2011;15(8):1636–1644. doi: 10.1111/j.1582-4934.2011.01317.x. PubMed DOI PMC

Ondracek J, Fadrus P, Sana J, et al. Global microRNA expression profiling identifies unique microrna pattern of radioresistant glioblastoma cells. Anticancer Res. 2017;37(3):1099–1104. doi: 10.21873/anticanres.11422. PubMed DOI

Kren L, Slaby O, Muckova K, et al. Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: an unexpected prognostic significance? Neuropathology. 2011;31(2):129–134. doi: 10.1111/j.1440-1789.2010.01149.x. PubMed DOI

Zhao H, Wang S, Song C, et al. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. World J Surg Oncol. 2016;14(1):261. doi: 10.1186/s12957-016-1012-4. PubMed DOI PMC

Karsy M, Neil JA, Guan J, et al. A practical review of prognostic correlations of molecular biomarkers in glioblastoma. Neurosurg Focus. 2015;38(3):E4. doi: 10.3171/2015.1.FOCUS14755. PubMed DOI

Piwecka M, Rolle K, Belter A, et al. Comprehensive analysis of microRNA expression profile in malignant glioma tissues. Mol Oncol. 2015;9(7):1324–1340. doi: 10.1016/j.molonc.2015.03.007. PubMed DOI PMC

Lakomy R, Sana J, Hankeova S, et al. MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci. 2011;102(12):2186–2190. doi: 10.1111/j.1349-7006.2011.02092.x. PubMed DOI PMC

Niyazi M, Andratschke N, Bendszus M, et al. ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma. Radiother Oncol. 2023;184:109663. doi: 10.1016/j.radonc.2023.109663. PubMed DOI

Galldiks N, Niyazi M, Grosu AL, et al. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. Neuro Oncol. 2021;23(6):881–893. doi: 10.1093/neuonc/noab013. PubMed DOI PMC

Albert NL, Weller M, Suchorska B, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016;18(9):1199–1208. doi: 10.1093/neuonc/now058. PubMed DOI PMC

Heiss P, Mayer S, Herz M, et al. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med. 1999;40:1367–1373. PubMed

Okubo S, Zhen HN, Kawai N, et al. Correlation of l-methyl- 11 C-methionine (MET) uptake with l-type amino acid transporter 1 in human gliomas. J Neurooncol. 2010;99(2):217–225. doi: 10.1007/s11060-010-0117-9. PubMed DOI

Nariai T, Tanaka Y, Wakimoto H, et al. Usefulness of L-[methyl- 11 C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg. 2005;103(3):498–507. doi: 10.3171/jns.2005.103.3.0498. PubMed DOI

Kracht LW, Friese M, Herholz K, et al. Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30(6):868–873. doi: 10.1007/s00259-003-1148-7. PubMed DOI

Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316–1322. doi: 10.1212/wnl.50.5.1316. PubMed DOI

Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972. doi: 10.1200/JCO.2009.26.3541. PubMed DOI

Niyazi M, Brada M, Chalmers AJ, et al. ESTRO-ACROP guideline “target delineation of glioblastomas”. Radiother Oncol. 2016;118(1):35–42. doi: 10.1016/j.radonc.2015.12.003. PubMed DOI

Scoccianti S, Detti B, Gadda D, et al. Organs at risk in the brain and their dose-constraints in adults and in children: a radiation oncologist’s guide for delineation in everyday practice. Radiother Oncol. 2015;114(2):230–238. doi: 10.1016/j.radonc.2015.01.016. PubMed DOI

Zobrazit více v PubMed

ClinicalTrials.gov
NCT05608395

Najít záznam

Citační ukazatele

    Možnosti archivace